Objective To evaluate the off-label use of lenalidomide using evidence-based medicine methods in the Second People's Hospital of Wuhu,in order to provide reference for promoting the rational use of new anti-tumor drugs in clinical practice.Methods Establish evaluation criteria and evidence-based medical evaluation process for the off-label use of new anti-tumor drugs in accordance with Evidence-Based Evaluation Specification for Off-label Drug Use and Authoritative Guidelines.Case data from inpatients that using lenalidomide were retrospectively investigated in the Second People's Hospital of Wuhu from January 2021 to December 2023,and the off-label drug use were statistically analyzed and reviewed by evidence-based evaluation criteria.Results A total of 87 cases using lenalidomide were collected from the hospital,of 39 cases were off-label drug use,accounting for 44.83%,the main categories of off-label drug use were indication,dosage,course of treatment.Among the off-label use of lenalidomide,64.10% were in the stage of relapsed/refractory treatment.The proportions of"recommended use""restricted use""special use"and"not recommended use"were 15.39%,56.41%,25.64%,2.56%,respectively.Conclusion The off-label use of lenalidomide is more common,and there are evaluation results indicating that it is not recommended to use.Medical institutions should strengthen the management of the off-label drug use.The evaluation criteria established by using evidence-based medicine methods provide reference value for evaluation of the off-label use of new anti-tumor drugs.
lenalidomideoff-label drug useevidence-based medicineevaluation criteriaindicationdosagecourse of treatment
NETL
NSTL
万方数据
